Vaxcyte’s stock soars 33% after trial shows positive data for pneumococcal vaccine

Vaxcyte Inc.’s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.